Interacting partners of FEN1 and its role in the development of anticancer therapeutics

Chandrasekhar Kathera; Jing Zhang; Avilala Janardhan; Hongfang Sun; Wajid Ali; Xiaolong Zhou; Lingfeng He; Zhigang Guo

doi:10.18632/oncotarget.15176

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Interacting partners of FEN1 and its role in the development of anticancer therapeutics

Chandrasekhar Kathera, Jing Zhang, Avilala Janardhan, Hongfang Sun, Wajid Ali, Xiaolong Zhou, Lingfeng He and Zhigang Guo _

PDF | HTML | How to cite

Oncotarget. 2017; 8:27593-27602. https://doi.org/10.18632/oncotarget.15176

Metrics: PDF 2911 views | HTML 3255 views | ?

Abstract

Chandrasekhar Kathera1,*, Jing Zhang1,*, Avilala Janardhan1, Hongfang Sun1, Wajid Ali1, Xiaolong Zhou2, Lingfeng He1 and Zhigang Guo1

1 Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China

2 The Laboratory of Animal Genetics, Breeding, and Reproduction, College of Animal Science and Technology, Zhejiang Agriculture and Forestry University, Hangzhou, China

* As co-first authors

Correspondence to:

Zhigang Guo, email:

Keywords: protein-protein interaction, small molecular inhibitors, FEN1, posttranslational, modifications

Received: December 14, 2016 Accepted: January 24, 2017 Published: February 07, 2017

Abstract

Protein-protein interaction (PPI) plays a key role in cellular communication, Protein-protein interaction connected with each other with hubs and nods involved in signaling pathways. These interactions used to develop network based biomarkers for early diagnosis of cancer. FEN1(Flap endonuclease 1) is a central component in cellular metabolism, over expression and decrease of FEN1 levels may cause cancer, these regulation changes of Flap endonuclease 1reported in many cancer cells, to consider this data may needs to develop a network based biomarker. The current review focused on types of PPI, based on nature, detection methods and its role in cancer. Interacting partners of Flap endonuclease 1 role in DNA replication repair and development of anticancer therapeutics based on Protein-protein interaction data.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15176

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Interacting partners of FEN1 and its role in the development of anticancer therapeutics

Abstract